Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates

Cash position of €6.8 million as of December 31, 2023



Financial visibility until the end of fourth quarter of 2024


...

Related Keywords

United States ,San Antonio ,Texas ,American ,Shefali Agarwal ,Nicolas Trebouta ,Robert Coleman ,American Association For Cancer Research ,Company Group ,Regulatory News ,Euronext Growth Paris ,Valerio Therapeutic ,Next Oncology ,Valerio Therapeutics ,Targeting Multiple Proteins ,Repair Pathways ,Inhibiting Different ,American Association ,Cancer Research ,Investigational New Drug ,Annual General Meeting ,Markets ,